Antibody-drug conjugates (ADCs) have been in development for decades, but only about a dozen have received FDA approval. Clearly, ADCs still have some major challenges. Yet they have done little to ...
DAEJEON, South Korea and NORTH BETHESDA, Md., Oct. 31, 2025 (GLOBE NEWSWIRE) -- IntoCell Inc. (KOSDAQ: 287840), a biotechnology company developing next-generation payload and linker technologies for ...
Data supporting the rationale for Baylink's innovative ADC linker technology enabling delivery of degraders, dual payload antibody drug conjugates, and high drug to antibody ratio chemotherapy will be ...
Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate (ADC) linker platform. The two companies have been working together ...
Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...
Antibody-drug conjugates (ADCs), also known as armed antibodies, are positioned to be a significant source of next-generation oncolytic therapies. There has been explosive growth in ADC R&D, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback